Cash GenerationRobust operating cash flows and improved free cash flow indicate durable ability to fund operations, R&D and selective M&A without relying solely on markets. This cash generation supports reinvestment and financial flexibility over the next several quarters.

Diversified End Markets & PartnershipsExposure to defense, medical and industrial markets plus strategic partnerships provides revenue diversification and access to large, recurring contracts. This mix reduces single-market cyclicality and strengthens multi-quarter revenue visibility and commercial stickiness.

Operational EfficiencySustained EBIT/EBITDA margins show the company manages operating expenses effectively despite margin headwinds. This operational efficiency supports cash flow resilience and reinvestment capacity in a capital-intensive photonics business over the medium term.

Bears Say

Margin PressureDeclining gross and net margins point to rising input costs or pricing pressure that can persist absent stronger pricing power or cost reductions. Prolonged margin compression would erode profitability, ROE and internal funding for growth across upcoming quarters.

Increasing LeverageA rising debt-to-equity trend increases financial leverage and interest burdens, reducing strategic flexibility. Higher leverage leaves less room to absorb cyclical shocks or fund additional R&D/acquisitions without increasing refinancing risk over the medium term.

High Capital Expenditure BurdenPersistent high capex requirements for manufacturing and R&D constrain free cash flow conversion and limit funds available for debt reduction or shareholder returns. Continued capex intensity may necessitate external funding or slower deleveraging over several quarters.

LBIRD FAQ

What was Lumibird SA’s price range in the past 12 months?

Lumibird SA lowest stock price was €7.70 and its highest was €24.30 in the past 12 months.

What is Lumibird SA’s market cap?

Lumibird SA’s market cap is €501.52M.

When is Lumibird SA’s upcoming earnings report date?

Lumibird SA’s upcoming earnings report date is Mar 17, 2026 which is in 22 days.

How were Lumibird SA’s earnings last quarter?

Lumibird SA released its earnings results on Sep 23, 2025. The company reported €0.223 earnings per share for the quarter, beating the consensus estimate of N/A by €0.223.

Is Lumibird SA overvalued?

According to Wall Street analysts Lumibird SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lumibird SA pay dividends?

Lumibird SA does not currently pay dividends.

What is Lumibird SA’s EPS estimate?

Lumibird SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lumibird SA have?

Lumibird SA has 22,466,883 shares outstanding.

What happened to Lumibird SA’s price movement after its last earnings report?

Lumibird SA reported an EPS of €0.223 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.505%.

Which hedge fund is a major shareholder of Lumibird SA?

Currently, no hedge funds are holding shares in FR:LBIRD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lumibird SA

Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, high power laser diodes, fiber lasers, fiber amplifiers and components, photonics solutions for time-of-flight lidar and range-finding, and doppler lidar systems for wind measurement. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The Medical division provides medical and ophthalmological solutions from diagnosis to laser treatment. The company was founded in 1970 and is headquartered in Lannion, France.